| NCT ID | NCT03131531 |
| Status | Recruiting |
| Phase | — |
| Sponsor | A.O. Ospedale Papa Giovanni XXIII |
| Condition | Hodgkin Lymphoma |
| Study Type | OBSERVATIONAL |
| Enrollment | 6,000 participants |
| Start Date | 2017-03-23 |
| Primary Completion | 2027-03-23 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 6,000 participants in total. It began in 2017-03-23 with a primary completion date of 2027-03-23.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This registry has been established to gain a better understanding of the clinical and biological characteristics and outcome of patients with lymphoid cancer
Eligibility Criteria
Inclusion Criteria: * Male or female patients 18 years or older * Written informed consent * Confirmed diagnosis of Hodgkin disease, non-Hodgkin lymphomas or myeloma Exclusion Criteria: \- Unconfirmed diagnosis of Hodgkin disease, non-Hodgkin lymphomas or myeloma
Contact & Investigator
Alessandro Rambaldi, MD
PRINCIPAL INVESTIGATOR
A.O. Ospedale Papa Giovanni XXIII
Frequently Asked Questions
Who can join the NCT03131531 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Hodgkin Lymphoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT03131531 currently recruiting?
Yes, NCT03131531 is actively recruiting participants. Contact the research team at arambaldi@asst-pg23.it for enrollment information.
Where is the NCT03131531 trial being conducted?
This trial is being conducted at Bergamo, Italy.
Who is sponsoring the NCT03131531 clinical trial?
NCT03131531 is sponsored by A.O. Ospedale Papa Giovanni XXIII. The principal investigator is Alessandro Rambaldi, MD at A.O. Ospedale Papa Giovanni XXIII. The trial plans to enroll 6,000 participants.